Posts in tag

PBAC


Trust between the government and community pharmacy is broken, Professor Trent Twomey, Pharmacy Guild of Australia national president believes  Labor’s decision to push ahead with its plans for 60-day dispensing …

The controversial decision to restrict prescribing fluticasone propionate for young children has been reversed in a move welcomed by the Guild But families and pharmacists have been left without clear …

Increasing dispensing limits from 30 to 60 days’ supply of medication through the Pharmaceutical Benefits Scheme (PBS) is back on the agenda  Ahead of the federal Budget in May, Mark …

PBAC gives OK to imports of drought-stricken Ozempic and Trulicity but won’t allow supplier to charge higher price  Emergency imported supplies of overseas supplies of shortage-plagued Ozempic (semaglutide) and Trulicity …

Decrease in esomeprazole and increase in pantoprazole scripts likely due to restriction changes, says PBAC, though full picture obscured by lack of OTC and private data Restriction changes established in …

PBAC recommends listing of adalimumab biosimilar The PBAC has recommended the Authority Required listing of adalimumab (Yuflyma) in the form of 40 mg in 0.4 mL pre-filled syringe and pre-filled …

Patients have been shifting to lower dose PPIs following PBS listing changes, review reveals, but more investigation is needed The Drug Utilisation Sub-Committee (DUSC) of the PBAC has found positive …

Pharmacy has a prominent role in the supply and provision of biosimilar medicines, and the profession has been slow to come to terms with this. Is the situation now changing? …

Mixed messages from the Department of Health over two-month prescriptions, as new documents say pharmacist mark-ups will impact consumer and taxpayer savings New Department of Health documents reveal that two-month …

Pharmacy group estimates average loss of $85k in gross profit per pharmacy if 60-day dispensing proposal goes forward With the 60-day dispensing proposal still on the table, the Rural Pharmacy …

Decision on PPI double dosing deferred by PBAC, but support given to antibiotic listing changes The Pharmaceutical Benefits Advisory Committee (PBAC) has deferred a decision on whether to allow twice …

Are two month prescriptions back on the government’s agenda? Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) that prescription lengths be doubled to two months for a range of medicines …